

Pre-Hospital Treatment of Asthma

Steven Kanarian, MPH, EMT-P

Dispatch



- You, are part of a paramedic / EMT ALS unit. You are dispatched to a reported “difficulty breathing.”

Initial Impression



- You arrive on scene.
- It is a residential address.
- Scene appears to be safe.
- You knock on the front door and hear “come in” from inside the house.

Initial Impression



- 38-year-old (y/o) male presents
 - Conscious and alert
 - Anxious
 - Pale, diaphoretic skin
 - Obvious difficulty breathing





Discussion



- *What is your initial impression of the patient's status?*
- *What are your next, most immediate actions?*



Initial Assessment



- You perform an initial assessment.
- Your partner prepares a non-rebreather mask.



Initial Assessment



- You note
 - Airway open
 - Lung sounds with inspiratory and expiratory wheezes all fields

Initial Assessment



- You also note
 - Respiration, 30 and shallow
 - Prolonged expiratory phase
 - Skin cool, pale, and slightly diaphoretic
 - Patient is able to speak in two- to three-word sentences.
 - Accessory muscle use
 - Patient looks weak. Head occasionally bobs.



Discussion




- *What can immediately be done to improve the patient's tidal volume?*

Treatment/Assessment



- Oxygen administered via nonrebreather mask
- Vital signs obtained



Initial Assessment



- History of present illness
 - Patient has a past medical history of asthma.
 - Metered-dose inhaler (MDI) medication ran out yesterday.
 - Patient woke with shortness of breath one hour ago.
 - He has gotten progressively worse.

Initial Assessment



- Vital signs
 - HR = 118 regular
 - RR = 32 shallow
 - BP = 130/72
 - SpO₂ = 90% on 15 Lpm
 - Capnograph obtained

Initial Assessment



- Capnograph waveform



- Interpretation?



Discussion



- *What do you think is responsible for the patient's breathing difficulty?*
- *Should this patient be intubated?*
- *What are your treatment priorities?*

Assessment/Treatment



- Nebulizer is prepared.
 - 2.5 mg albuterol
 - 500 mcg ipratropium bromide



Assessment/Treatment



- Patient is placed on cardiac monitor.
- Nebulized medications are administered.





Discussion



- *What additional medications may be considered?*

Treatment




- Reassessment is performed. No improvement after treatment is noted.
- Epinephrine 1:1,000, 0.3 mg IM x 1



Detailed Assessment



- Cardiac rhythm



- Interpretation?

Treatment



- IV access obtained





Discussion



- *What is your determination of the patient's condition?*

Treatment



- Patient moved to ambulance
- Transport to ED initiated





Discussion



- *What are your priorities during transport?*

Ongoing Assessment



- Reassessment reveals slight improvement in patient's condition.
 - Patient states he is doing better.
 - Lung sounds improving
 - SpO₂ increased to 92% on 15 Lpm
 - “Shark fin” capnograph flattening out



Assessment



- Capnograph waveform



- Interpretation?

Ongoing Assessment



- Report is given to ED.



Ongoing Assessment



- Reassessment reveals further improvement in patient's condition.
 - Lung sounds improving
 - SpO₂ increased to 97% on 15 Lpm
 - Anxiety relieved
 - No accessory muscle use
 - Skin cool, slightly diaphoretic, good color

Treatment



- Patient is prepared for transfer to ED staff.



ED Treatment and Beyond



- The patient is admitted into an ED bed.
- A second IV is placed.
 - Blood drawn for routine studies
- Patient is placed on a cardiac monitor with continuous pulse oximetry and capnography.

ED Treatment and Beyond



- Peak flow is measured using a peak flow meter to obtain a baseline value to monitor further treatment and quantify improvement or detect deterioration.
- The patient continued to wheeze, and the HR was 130/min after the first nebulizer and epinephrine administered by EMS.

ED Treatment and Beyond



- Racemic epinephrine (Xoponex) nebulizer administered in an effort to minimize further adrenergic stimulation.
- Solumedrol 125 mg IV x 1 was administered, given the severity of the asthma exacerbation.
- Magnesium 2 g IV x 1 was also administered.

ED Treatment and Beyond



- .
- After a few more rounds of nebulizers the patient's potassium was rechecked and found to be 3.1 mEq/L. The patient had potassium added to his IV fluids.

ED Treatment and Beyond



- Attempts were made to admit the patient to an ICU bed.
 - None was available.
- The patient continued to receive treatment and monitoring in the ED until nebulizers were spaced out to q4h.

Drug Calculation Review



Administration of Mag. Sulfate =
2 grams in 100 cc over 20 minutes

$$(100 \text{ cc} / 20 \text{ minutes}) \times 60 \text{ gtts/ min} =$$
$$300 \text{ gtts/minute}$$

Review Material

case 1



Epidemiology



- CDC reports that in 2001, 20.3 million people in U.S. had asthma.
 - 12 million had an asthma attack in the previous year.
 - Prevalence of 5%–10% in children
 - Prevalence of 7%–10% in elderly
- Half of cases develop before age 10.
 - Most common chronic disease of childhood




Epidemiology



- Prevalence of exercise-induced asthma
3%–10% of general population
- 40%–90% in persons with asthma
- Estimated 500,000 hospitalizations and
5,000 deaths annually
- Occurs predominantly in males in
childhood (2:1)
 - Equalizes by puberty/early adulthood



A&P Review





A&P Review



Lower Airway


- Trachea
- Mainstem bronchi
- Bronchioles
- Tertiary bronchioles
- Respiratory bronchioles
- Alveolar ducts
- Alveolar sac
- Alveoli



Smooth
muscle control




A&P Review






A&P Review





A&P Review






A&P Review



- Respiratory epithelium
 - Goblet cells
 - Mucous layer
 - Ciliated columnar epithelial cells





Animation




Asthma Animation



Pathophysiology



- Pathophysiology includes
 - Bronchial hyperresponsiveness
 - Smooth muscle constriction
 - Mucous production
 - Airway inflammation
 - Can be acute, chronic






Pathophysiology



- Asthma triggers
 - Medication sensitivity
 - Allergens
 - Pollen
 - Pet dander
 - Irritants
 - Paint fumes, cleaning product fumes
 - Exercise
 - Viral respiratory infections
 - Cold, dry air





Pathophysiology



- Mucous production
 - Increase in number of respiratory epithelial goblet cells
 - Chronic mucous plug formation
 - Chronic mucous plugs consist of mixture of serum proteins, inflammatory cells, and cell debris.
 - May take weeks to clear



Pathophysiology



- Airway inflammation: acute
 - Result of recruitment of cells to airway
 - Mast cells
 - Histamine and other mediator release
 - Intense, immediate inflammatory reaction
 - Eosinophils, T lymphocytes, macrophages, neutrophils
 - Additional mediator release
 - Contribute to inflammation



Pathophysiology



- Airway inflammation: chronic
 - Characterized by persistent epithelial cell damage and repair process
 - Epithelial cells, myofibroblasts deposit interstitial collagen
 - Fibroblasts release cytokines = inflammation
 - Result in microscopic changes to airway
 - Thickening of basement membrane




Pathophysiology



- Two phases of an asthma exacerbation
 - Phase 1
 - One to two hours after exposure to trigger
 - Bronchoconstriction secondary to histamine release
 - Mild airway edema
 - Phase 2
 - Six to eight hours after exposure to trigger
 - Invasion of respiratory epithelium by immune cells
 - Significant edema, swelling, mucous production



Pathophysiology





Pathophysiology



- Wheezing occurs as narrowed airways begin to obstruct air flow.
- Early in exacerbation, wheezing is heard at end of expiratory phase.
 - Wheezing moves toward beginning of expiratory phase, then into inspiratory phase as airflow restriction worsens.



Clinical Assessment



- Symptoms
 - Classic triad is dyspnea, wheezing, and cough.
 - Chest tightness
 - Sputum production



Clinical Assessment



- Signs
 - Tachycardia, tachypnea
 - Pulsus paradoxus
 - Wheezing, decreased breath sounds
 - Prolonged expiratory phase
 - Chest hyperinflation
 - Hyperresonance to percussion
 - Pale, cool, diaphoretic skin



Clinical Assessment



- Signs of severe exacerbation
 - Decreasing level of consciousness
 - Absent lung sounds
 - Accessory muscle use
 - Cyanosis



Clinical Assessment



- SpO₂
 - Decreased
- ETCO₂
 - Decreased early in exacerbation secondary to hyperventilation
 - Normal, elevated later in exacerbation
- Capnogram
 - “Shark fin” appearance



Clinical Assessment



- Capnography: early asthma
 - Beginnings of “shark fin” appearance
 - Increased rate
 - Decreased peak ETCO_2 secondary to hyperventilation
 - Patient “blows off” CO_2



Normal Endtidal CO₂


A-B: Early Exhalation, CO₂ free (dead space)



B-C: Combination of dead space and alveolar gas

C-D: Alveolar plateau

D: End Tidal CO₂

D-E: Inhalation





Depth = Height



Clinical Assessment



- Capnography
 - “Shark fin” appearance to waveform
 - Loss of alveolar plateau
 - May have elevated baseline secondary to air trapping






Clinical Assessment



- Compare with normal waveform.





Clinical Assessment



Phases of Acute Asthma Exacerbation

Phase	Clinical Assessment	ETCO ₂ Levels (mm Hg)
Mild	Hyperventilating	< 35
Moderate	Tiring	35 – 50
Sever	Tired	>



Clinical Assessment



- Spirometry
 - Forced expiratory volume (FEV₁)
 - Determined when patient in normal health, not during acute exacerbation
 - Useful in determining general severity of patient's disease
 - Peak expiratory flow rate (PEFR)
 - Sequential measurements useful to determine response to therapy



Treatment



- Ensure patent airway
 - BLS, ALS intervention if necessary
 - Do not be overeager to perform endotracheal intubation
 - Numerous complications associated with intubation and mechanical ventilation of asthmatics



Treatment



- Decision to intubate the asthmatic patient is multifactorial.
- Guidelines
 - $p\text{CO}_2$ exceeding 40 mmHg
 - $p\text{O}_2$ less than 60
 - Labored breathing and accessory muscle use
 - Potential or developing myocardial ischemia
 - Declining mental status
 - Hemodynamic instability



Treatment




- Ensure adequate oxygenation and ventilation.
 - High-flow, 100% O₂ via nonrebreather mask
 - BVM assist if necessary
- IV initiation
 - Consider need for fluid administration.



Treatment



- Nebulized adrenergic agents
 - β -2 agents preferred
 - Albuterol





Treatment



- Percutaneous adrenergic agents
 - Epinephrine 1:1000
 - SQ administration
 - Terbutaline
 - SQ administration





Treatment



- Anticholinergic agents
 - Nebulized ipratropium bromide
 - Cumulative effect when administered with β -2 adrenergic agents





Treatment



- Corticosteroids
 - Highly effective in treatment of asthma
 - Onset of action, four to six hours
 - Methylprednisolone IV
 - Fluticasone





Treatment



- Magnesium sulfate
 - Smooth muscle relaxant
 - Indicated in severe exacerbations



Treatment: Hospital



- Theophylline
 - Provides bronchodilation of the small airways; improves respiratory muscle endurance
 - Administered IV infusion
 - Extremely toxic
 - Risk of seizures, cardiac dysrhythmias at plasma levels >30 mcg/mL



Treatment: Hospital



- Mast cell modifiers
 - Control mast cell media
eosinophil recruitment
 - Decrease airway inflam
bronchospasm
 - Examples
 - Cromolyn, nedocromil





Remember



- BLS:
 - Oxygen
 - Limit exertion
 - Reassure the patient



Thank You



For info on how to get a head start
on medic class:

<http://stevenkanarian.wordpress.com>

References

- Bledsoe, B. E., Porter, R. S., and Cherry, R. A. *Paramedic Care: Principles and Practice*. Vol. 3, 2nd ed. Upper Saddle River, NJ: Pearson Prentice Hall, 2006.
- Chang, A. K., and Barton, E. D. “Pneumothorax: Iatrogenic, spontaneous and pneumomediastinum.” www.emedicine.com (accessed March 16, 2007; last updated March 23, 2005).
- Cydulka, R. K. “Acute asthma in adults.” In: *Emergency Medicine: A Comprehensive Study Guide*, 6th ed., edited by J. E. Tintinalli, G. D. Kelen, and J. S. Stapczynski. New York: McGraw-Hill, 2004.
- Kleinschmidt, P. “Chronic obstructive pulmonary disease and emphysema.” www.emedicine.com (accessed April 1, 2007; last updated January 24, 2007).
- Li, J., and Brainard, D. “Tuberculosis.” www.emedicine.com (accessed February 13, 2007; last updated March 13, 2006).
- Moffa, Jr., M. A., and Emerman, and C. L. “Bronchitis, pneumonia, and pleural empyema.” In: *Emergency Medicine: A Comprehensive Study Guide*, 6th ed., edited by J. E. Tintinalli, G. D. Kelen, and J. S. Stapczynski. New York: McGraw-Hill, 2004.